Effect of Thyrotropin Suppression Therapy on Bone in Thyroid Cancer Patients
dc.contributor.author | Papaleontiou, Maria | |
dc.contributor.author | Hawley, Sarah T. | |
dc.contributor.author | Haymart, Megan R. | |
dc.date.accessioned | 2017-12-15T16:47:30Z | |
dc.date.available | 2017-12-15T16:47:30Z | |
dc.date.issued | 2016-02 | |
dc.identifier.citation | Papaleontiou, Maria; Hawley, Sarah T.; Haymart, Megan R. (2016). "Effect of Thyrotropin Suppression Therapy on Bone in Thyroid Cancer Patients." The Oncologist 21(2): 165-171. | |
dc.identifier.issn | 1083-7159 | |
dc.identifier.issn | 1549-490X | |
dc.identifier.uri | https://hdl.handle.net/2027.42/139948 | |
dc.publisher | Wiley Periodicals, Inc. | |
dc.publisher | AlphaMed Press | |
dc.subject.other | Thyroid neoplasms | |
dc.subject.other | Risk | |
dc.subject.other | Bone density | |
dc.subject.other | Thyrotropin | |
dc.title | Effect of Thyrotropin Suppression Therapy on Bone in Thyroid Cancer Patients | |
dc.type | Article | en_US |
dc.rights.robots | IndexNoFollow | |
dc.subject.hlbsecondlevel | Hematology and Oncology | |
dc.subject.hlbtoplevel | Health Sciences | |
dc.description.peerreviewed | Peer Reviewed | |
dc.contributor.affiliationum | Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA | |
dc.contributor.affiliationum | Division of Metabolism, Endocrinology and Diabetes, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA | |
dc.contributor.affiliationum | Division of Hematology/Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA | |
dc.description.bitstreamurl | https://deepblue.lib.umich.edu/bitstream/2027.42/139948/1/onco0165.pdf | |
dc.identifier.doi | 10.1634/theoncologist.2015-0179 | |
dc.identifier.source | The Oncologist | |
dc.identifier.citedreference | I Sugitani, Y Fujimoto. Effect of postoperative thyrotropin suppressive therapy on bone mineral density in patients with papillary thyroid carcinoma: A prospective controlled study. Surgery. 2011; 150: 1250 – 1257. | |
dc.identifier.citedreference | E Jódar, M Begoña López, L García. Bone changes in pre‐ and postmenopausal women with thyroid cancer on levothyroxine therapy: Evolution of axial and appendicular bone mass. Osteoporos Int. 1998; 8: 311 – 316. | |
dc.identifier.citedreference | I Karner, Z Hrgović, S Sijanović. Bone mineral density changes and bone turnover in thyroid carcinoma patients treated with supraphysiologic doses of thyroxine. Eur J Med Res. 2005; 10: 480 – 488. | |
dc.identifier.citedreference | C Marcocci, F Golia, G Bruno‐Bossio. Carefully monitored levothyroxine suppressive therapy is not associated with bone loss in premenopausal women. J Clin Endocrinol Metab. 1994; 78: 818 – 823. | |
dc.identifier.citedreference | CG Müller, TA Bayley, JE Harrison. Possible limited bone loss with suppressive thyroxine therapy is unlikely to have clinical relevance. Thyroid. 1995; 5: 81 – 87. | |
dc.identifier.citedreference | TL Paul, J Kerrigan, AM Kelly. Long‐term l ‐thyroxine therapy is associated with decreased hip bone density in premenopausal women. JAMA. 1988; 259: 3137 – 3141. | |
dc.identifier.citedreference | G Pioli, M Pedrazzoni, E Palummeri. Longitudinal study of bone loss after thyroidectomy and suppressive thyroxine therapy in premenopausal women. Acta Endocrinol (Copenh). 1992; 126: 238 – 242. | |
dc.identifier.citedreference | DS Ross, RM Neer, EC Ridgway. Subclinical hyperthyroidism and reduced bone density as a possible result of prolonged suppression of the pituitary‐thyroid axis with l ‐thyroxine. Am J Med. 1987; 82: 1167 – 1170. | |
dc.identifier.citedreference | S Tournis, JD Antoniou, CG Liakou. Volumetric bone mineral density and bone geometry assessed by peripheral quantitative computed tomography in women with differentiated thyroid cancer under TSH suppression. Clin Endocrinol (Oxf). 2015; 82: 197 – 204. | |
dc.identifier.citedreference | LY Wang, AW Smith, FL Palmer. Thyrotropin suppression increases the risk of osteoporosis without decreasing recurrence in ATA low‐ and intermediate‐risk patients with differentiated thyroid carcinoma. Thyroid. 2015; 25: 300 – 307. | |
dc.identifier.citedreference | C‐Y Guo, AP Weetman, R Eastell. Longitudinal changes of bone mineral density and bone turnover in postmenopausal women on thyroxine. Clin Endocrinol (Oxf). 1997; 46: 301 – 307. | |
dc.identifier.citedreference | F Hawkins, D Rigopoulou, K Papapietro. Spinal bone mass after long‐term treatment with l ‐thyroxine in postmenopausal women with thyroid cancer and chronic lymphocytic thyroiditis. Calcif Tissue Int. 1994; 54: 16 – 19. | |
dc.identifier.citedreference | AWC Kung, T Lorentz, SCF Tam. Thyroxine suppressive therapy decreases bone mineral density in post‐menopausal women. Clin Endocrinol (Oxf). 1993; 39: 535 – 540. | |
dc.identifier.citedreference | TG De Melo, da LV Assumpção, AO Santos. Low BMI and low TSH value as risk factors related to lower bone mineral density in postmenospausal women under levothyroxine therapy for differentiated thyroid carcinoma. Thyroid Res. 2015; 8: 7. | |
dc.identifier.citedreference | JL Reverter, E Colomé, S Holgado. Bone mineral density and bone fracture in male patients receiving long‐term suppressive levothyroxine treatment for differentiated thyroid carcinoma. Endocrine. 2010; 37: 467 – 472. | |
dc.identifier.citedreference | C Marcocci, F Golia, E Vignali. Skeletal integrity in men chronically treated with suppressive doses of l ‐thyroxine. J Bone Miner Res. 1997; 12: 72 – 77. | |
dc.identifier.citedreference | B Biondi, DS Cooper. Benefits of thyrotropin suppression versus the risks of adverse effects in differentiated thyroid cancer. Thyroid. 2010; 20: 135 – 146. | |
dc.identifier.citedreference | International Osteoporosis Foundation. Osteoporosis in men: Why change needs to happen. Available at: http://share.iofbonehealth.org/WOD/2014/thematic‐report/WOD14‐Report.pdf. Accessed April 1, 2015. | |
dc.identifier.citedreference | L Gennari, JP Bilezikian. Osteoporosis in men. Endocrinol Metab Clin North Am. 2007; 36: 399 – 419. | |
dc.identifier.citedreference | SE Roberts, MJ Goldacre. Time trends and demography of mortality after fractured neck of femur in an English population, 1968‐98: Database study. BMJ. 2003; 327: 771 – 775. | |
dc.identifier.citedreference | MJ Goldacre, SE Roberts, D Yeates. Mortality after admission to hospital with fractured neck of femur: Database study. BMJ. 2002; 325: 868 – 869. | |
dc.identifier.citedreference | MJ Parker, JK Anand. What is the true mortality of hip fractures?. Public Health. 1991; 105: 443 – 446. | |
dc.identifier.citedreference | JA Cauley, DE Thompson, KC Ensrud. Risk of mortality following clinical fractures. Osteoporos Int. 2000; 11: 556 – 561. | |
dc.identifier.citedreference | Surveillance, Epidemiology, and End Results Program. SEER Stat Fact Sheets: Thyroid Cancer. Available at http://seer.cancer.gov/statfacts/html/thyro.html. Accessed April 1, 2015. | |
dc.identifier.citedreference | Haugen BR, Alexander EK, Bible KC et al. American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2015 [Epub ahead of print] | |
dc.identifier.citedreference | B Biondi, S Filetti, M Schlumberger. Thyroid‐hormone therapy and thyroid cancer: A reassessment. Nat Clin Pract Endocrinol Metab. 2005; 1: 32 – 40. | |
dc.identifier.citedreference | P Roger, M Taton, J Van Sande. Mitogenic effects of thyrotropin and adenosine 3′,5′‐monophosphate in differentiated normal human thyroid cells in vitro. J Clin Endocrinol Metab. 1988; 66: 1158 – 1165. | |
dc.identifier.citedreference | R Baliram, L Sun, J Cao. Hyperthyroid‐associated osteoporosis is exacerbated by the loss of TSH signaling. J Clin Invest. 2012; 122: 3737 – 3741. | |
dc.identifier.citedreference | E Abe, RC Marians, W Yu. TSH is a negative regulator of skeletal remodeling. Cell. 2003; 115: 151 – 162. | |
dc.identifier.citedreference | SH Downs, N Black. The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non‐randomised studies of health care interventions. J Epidemiol Community Health. 1998; 52: 377 – 384. | |
dc.identifier.citedreference | JA Franklyn, J Betteridge, J Daykin. Long‐term thyroxine treatment and bone mineral density. Lancet. 1992; 340: 9 – 13. | |
dc.identifier.citedreference | G Görres, A Kaim, A Otte. Bone mineral density in patients receiving suppressive doses of thyroxine for differentiated thyroid carcinoma. Eur J Nucl Med. 1996; 23: 690 – 692. | |
dc.identifier.citedreference | AC Heijckmann, MSP Huijberts, P Geusens. Hip bone mineral density, bone turnover and risk of fracture in patients on long‐term suppressive l ‐thyroxine therapy for differentiated thyroid carcinoma. Eur J Endocrinol. 2005; 153: 23 – 29. | |
dc.identifier.citedreference | J Lehmke, U Bogner, D Felsenberg. Determination of bone mineral density by quantitative computed tomography and single photon absorptiometry in subclinical hyperthyroidism: A risk of early osteopaenia in post‐menopausal women. Clin Endocrinol (Oxf). 1992; 36: 511 – 517. | |
dc.identifier.citedreference | JJ Stĕpán, Z Límanová. Biochemical assessment of bone loss in patients on long‐term thyroid hormone treatment. Bone Miner. 1992; 17: 377 – 388. | |
dc.identifier.citedreference | J Toivonen, R Tähtelä, K Laitinen. Markers of bone turnover in patients with differentiated thyroid cancer with and following withdrawal of thyroxine suppressive therapy. Eur J Endocrinol. 1998; 138: 667 – 673. | |
dc.identifier.citedreference | CH Chen, JF Chen, BY Yang. Bone mineral density in women receiving thyroxine suppressive therapy for differentiated thyroid carcinoma. J Formos Med Assoc. 2004; 103: 442 – 447. | |
dc.identifier.citedreference | T Diamond, L Nery, I Hales. A therapeutic dilemma: Suppressive doses of thyroxine significantly reduce bone mineral measurements in both premenopausal and postmenopausal women with thyroid carcinoma. J Clin Endocrinol Metab. 1991; 72: 1184 – 1188. | |
dc.identifier.citedreference | S Giannini, M Nobile, L Sartori. Bone density and mineral metabolism in thyroidectomized patients treated with long‐term l ‐thyroxine. Clin Sci (Lond). 1994; 87: 593 – 597. | |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.